• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Biofrontera AG

    3/9/22 2:35:54 PM ET
    $BFRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRA alert in real time by email
    POS AM 1 form-posam.htm

     

    As filed with the United States Securities and Exchange Commission on March 9, 2022

     

    Registration No. 333-236021

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    Post-Effective

    Amendment No. 1 to

    Form F-3

    Registration Statement

    Under the Securities Act of 1933

     

     

     

    BIOFRONTERA AG

    (Exact Name of Registrant as Specified in its Charter)

     

    N/A

    (Translation of Registrant’s Name into English)

     

     

     

    Federal Republic of Germany   Not Applicable

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer
    Identification No.)

     

    Hemmelrather Weg 201

    D-51377 Leverkusen Germany

    Telephone: 011 49 214 876 00

    (Address and telephone number of Registrant’s principal executive office)

     

     

     

    Biofrontera Inc.

    120 Presidential Way

    Suite 330

    Woburn, MA 01801

    Telephone: 781 245 1325

    (Name, address, and telephone number of agent for service)

     

     

     

    Copies to:

    Stephen E. Older

    McGuireWoods LLP

    1251 Avenue of the Americas

    20th Floor

    New York, NY 10020

    Telephone: 212 548 2100

    Facsimile: 212 548 2150

     

    Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

     

    If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    DEREGISTRATION OF UNSOLD SECURITIES

     

    This Post-Effective Amendment is being filed to deregister unsold securities of Biofrontera AG, a German stock corporation (the “Registrant”), that were registered on the Registration Statement on Form F-3 (Commission File No. 333-236021) which was declared effective by the Securities and Exchange Commission on February 18, 2020 (the “Registration Statement”). The Registration Statement registered the sale of up to $100,000,000 of the Registrant’ securities and as of March 9, 2022, securities in the amount of $8,911,133.36 have been sold under the Registration Statement.

     

    The Registrant intends to file on March 9, 2022 a Form 15F serving as a certification of termination of registration of the unsold securities under Section 12(g) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and of the Registrant’s duty to file reports under Section 13(a) or Section 15(d) of the Exchange Act pursuant to Rule 12h-6(a).

     

    As a result of the termination of Exchange Act registration and the Registrant’s reporting obligation, the Registrant hereby terminates the effectiveness of the Registration Statement and, in accordance with undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities that had been registered but remained unsold at the termination of the offering, removes from registration any and all securities of the Registrant registered, but unsold, under the Registration Statement as of the date hereof.

     

    2
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in Leverkusen, Germany, on March 9, 2022.

     

      BIOFRONTERA AG
         
      By: /s/ Ludwig Lutter             
      Name:  Ludwig Lutter
      Title: Chief Financial Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
           

    /s/ Ludwig Lutter

    Ludwig Lutter

     

    Chief Financial Officer

    (Principal Executive Officer)

      March 9, 2022
           

    /s/ Hans-Dieter Stock

    Hans-Dieter Stock

     

    VP Controlling

    (Principal Accounting Officer)

      March 9, 2022
           

    /s/ Jörgen Tielmann

    Dr. Jörgen Tielmann

      Vice chairman of supervisory board   March 9, 2022
             
    /s/ Helge Lubenow   Member of supervisory board   March 9, 2022
    Dr. Helge Lubenow        
             

    /s/ Heikki Lanckriet

    Dr. Heikki Lanckriet

      Member of supervisory board   March 9, 2022

     

    3

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the United States Securities Act of 1933, as amended, the undersigned, the registrant’s duly authorized representative in the United States, has signed this Post-Effective Amendment, solely in the capacity of the duly authorized representative, on this March 9, 2022.

     

      Biofrontera Inc.
         
      By: /s/ Daniel Hakansson
      Name: Daniel Hakansson
      Title: Corporate Counsel

     

    4

    Get the next $BFRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRA
    Financials

    Live finance-specific insights

    See more
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

      Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co

      11/9/21 5:45:49 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

      Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea

      8/12/21 8:55:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

      Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the

      2/14/22 2:05:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG announces mediation results

      Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021

      11/19/21 8:45:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Biofrontera Ag claimed ownership of 8,000,000 shares

      3 - Biofrontera AG (0001712641) (Reporting)

      10/28/21 9:46:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BFRA
    SEC Filings

    See more
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      2/25/22 4:01:31 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      12/21/21 4:01:09 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      11/29/21 4:01:24 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Biofrontera AG

      EFFECT - Biofrontera AG (0001712641) (Filer)

      3/14/22 12:15:06 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Biofrontera AG

      15F-12B - Biofrontera AG (0001712641) (Filer)

      3/9/22 4:27:42 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Biofrontera AG

      POS AM - Biofrontera AG (0001712641) (Filer)

      3/9/22 2:35:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care